Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.47 |
| ▸ | ACACB | O00763 | 13/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15908998 | 0.87 | GRIN2B (0.50) | GRIN2BACACBFFAR1HCRTR1HCRTR2 | |
| SCHEMBL15908952 | 0.85 | GRIN2B (0.48) | GRIN2BACACBFFAR1HCRTR1HCRTR2 | |
| SCHEMBL15909325 | 0.84 | GRIN2B (0.47) | GRIN2BACACBFFAR1HRH3 | |
| SCHEMBL15908938 | 0.82 | GRIN2B (0.42) | GRIN2BACACBFFAR1HCRTR1HCRTR2 | |
| SCHEMBL15909042 | 0.82 | GRIN2B (0.45) | GRIN2BACACBFFAR1HCRTR1HCRTR2 | |
| SCHEMBL15908970 | 0.81 | GRIN2B (0.44) | GRIN2BACACBFFAR1HCRTR1HCRTR2 | |
| SCHEMBL15908905 | 0.78 | GRIN2B (0.47) | GRIN2BACACBFFAR1HCRTR1HCRTR2 | |
| SCHEMBL65166 | 0.78 | GRIN2B (0.53) | GRIN2BACACBFFAR1HCRTR1HCRTR2 | |
| SCHEMBL16497829 | 0.78 | GRIN2B (0.53) | GRIN2BACACBFFAR1HCRTR1HCRTR2 | |
| SCHEMBL1335289 | 0.78 | GRIN2B (0.56) | GRIN2BACACBFFAR1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294854-A1 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | US | claimed |
| US-8796470-B2 | Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators | ABBVIE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20110294854-A1 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294854-A1 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | ORAI1, CACNA1E, RYR1 | GRIN2B 183/4885ACACB 2727/4885FFAR1 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.